Teladoc Health (TDOC) Stock Looks Reasonable As Shares Stay Down 96%

Teladoc Health has seen its share price grind lower over the years, even as it pushes new telehealth tools into hospitals and clinics. This raises a straightforward question for you as an investor: Is the current US$5.77 price properly anchored to the cash flows the business can realistically produce?

• Over the past 5 years the stock has fallen 95.7%, so the market has already repriced a huge amount of optimism and that reset now frames any discussion of what its future cash flows are worth.
• The launch of AI features like SoloVitals and SoloScribe aims to make each virtual visit more efficient and clinically useful, which can support expectations for how much cash the company may ultimately generate from its installed base of care locations.
• Prefer to judge Teladoc Health on sales? See what Teladoc Health's 0.4x P/S says about the price.

The issue now is whether Teladoc Health's current market value is well supported by the cash flows implied by a Discounted Cash Flow (DCF) view.

If you are weighing Teladoc Health on its cash flows and AI push, it can help to benchmark against other healthcare AI players surfaced by a focused screen such as 34 healthcare AI stocks.

Is Teladoc Health a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) approach looks at the cash Teladoc Health can generate for shareholders and brings those future amounts back into today’s dollars. Teladoc Health produced about $120.2 million of free cash flow over the last twelve months, and the DCF framework here assumes those cash flows continue growing rather than shrinking. That projected stream, when discounted, points to an intrinsic worth that sits substantially above the current $5.77 share price.

Those projections build in free cash flow that trends higher into the early 2030s, which implies the business is expected to keep scaling its existing telehealth footprint instead of stalling out. The recent rollout of SoloVitals and SoloScribe supports that thesis because more efficient virtual visits can give each existing care location more economic weight, yet the market is still pricing the stock as if that potential is worth considerably less. You can see how the full DCF range compares with today’s quote in the detailed model output. Find out what Teladoc Health could be worth using our Discounted Cash Flow (DCF) estimate.

The Teladoc Health Narrative: What Would Justify Today's Price?

Narratives for Teladoc Health pick up where the valuation puzzle leaves off and describe which paths for growth, profitability and earnings would need to unfold for the stock to be worth materially more or less than today’s price. These narratives are available on Simply Wall St’s Community page. Each one connects its number to a concrete view of how Teladoc Health's growth, margins and risks could change, giving you something to revisit as new information becomes available.

Bulls on Teladoc Health see a cash generative reset story, while bears think the risks around mental health and reimbursement still weigh heavier.

Bull case: 62% undervalued

"Teladoc’s early struggles mirror this exact dynamic, but its true inflection point arrived when it solved the 'who pays' equation through deep integration with health insurance payers..."

Discover why this Narrative puts Teladoc Health at 62% undervalued.

Bear case: roughly fairly valued

"Margin pressures are likely to intensify due to lower unit economics as BetterHelp's insurance-based mental health revenues scale, since insurance reimbursement yields significantly lower gross profits than the legacy cash pay business..."

Explore why this Narrative puts Teladoc Health at roughly fairly valued.

One more Teladoc Health check that belongs beside the price tag

Numbers on Teladoc Health only tell part of the story, because the research screen has also flagged specific concerns that investors often weigh carefully before getting comfortable with any valuation. Take a closer look at 2 warning signs before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com